Maria-Luisa Maccecchini net worth and biography

Maria-Luisa Maccecchini Biography and Net Worth

CEO of Annovis Bio

Dr. Maccecchini founded Annovis in May 2008 to develop better therapeutics for Alzheimer’s, Parkinson’s and other neurodegenerative diseases. Was partner and director of two angel groups, Robin Hood Ventures and MidAtlantic Angel Group; Founder and CEO of Symphony Pharmaceuticals/Annovis a biotech company that sold in 2001 to Transgenomic; General Manager of Bachem Bioscience, the US subsidiary of Bachem AG, Switzerland and Head Molecular Biology Mallinckrodt; Dr. Maccecchini did one postdoc at Caltech and one at the Roche Institute of Immunology, her PhD in biochemistry is from the Biocenter of Basel with a two-year visiting fellowship at The Rockefeller University.

How do I contact Maria-Luisa Maccecchini?: The corporate mailing address for Dr. Maccecchini and other Annovis Bio executives is 1055 Westlakes Drive Suite 300, Berwyn PA, 19312. Annovis Bio can also be reached via phone at 610-727-3913 and via email at [email protected]. Learn More on Maria-Luisa Maccecchini's contact information.
Has Maria-Luisa Maccecchini been buying or selling shares of Annovis Bio?: Maria-Luisa Maccecchini has not been actively trading shares of Annovis Bio in the last ninety days. Most recently, on Monday, October 11th, Maria-Luisa Maccecchini bought 18,000 shares of Annovis Bio stock. The stock was acquired at an average cost of $27.61 per share, with a total value of $496,980.00. Learn More on Maria-Luisa Maccecchini's trading history.
Who are Annovis Bio's active insiders?: Annovis Bio's insider roster includes Claudine Bruck (Director), Maria-Luisa Maccecchini (CEO), and Reid McCarthy (Director). Learn More on Annovis Bio's active insiders.

Maria-Luisa Maccecchini Insider Trading History at Annovis Bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
10/11/2021	Buy	18,000	$27.61	$496,980.00

Maria-Luisa Maccecchini Buying and Selling Activity at Annovis Bio

Annovis Bio Company Overview

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

Today's Range

Now: $6.34

$6.34

$7.21

50 Day Range

MA: $8.08

$6.51

$9.88

2 Week Range

Now: $6.34

$4.53

$22.49

Volume

471,770 shs

Average Volume

217,290 shs

Market Capitalization

$87.49 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.59

The 2024 TECH RESET

From InvestorPlace | Ad

Are we on the edge of the biggest ‘TECH RESET’ in decades?

Click here for the step-by-step details